Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure.

Barbora Judita Kasperova Milos Mraz Petr Svoboda Daniel Hlavacek Helena Kratochvilova Istvan Modos Nikola Vrzackova Peter Ivak Petra Janovska Tatyana Kobets Jakub Mahrik Martin Riecan Lenka Steiner Mrazova Viktor Stránecký Ivan Netuka Tomáš Čajka Ondřej Kuda Vojtech Melenovsky Sona Stemberkova Hubackova Martin Haluzík

Published in: Cardiovascular diabetology (2024)

Our results show decreased inflammation in EAT of patients with severe heart failure treated by SGLT-2i, as compared to patients with heart failure without this therapy. Modulation of EAT inflammatory and metabolic status could represent a novel mechanism behind SGLT-2i-associated cardioprotective effects in patients with heart failure.

Keyphrases

heart failure
adipose tissue
oxidative stress
anti inflammatory
early onset
left ventricular
cardiac resynchronization therapy
insulin resistance
acute heart failure
atrial fibrillation
high fat diet
stem cells
type diabetes
drug induced
newly diagnosed